Merger (Tables)

12 Months Ended

Dec. 31, 2022

Schedule of Estimated Fair Value Consideration

The estimated fair value of total consideration given was $110.4 million as detailed below and is based on 3,208,718 shares of common stock, after taking into account the Reverse Stock Split, outstanding immediately prior to the Effective Time.


Number of common shares of the combined company to be owned by Aerpio shareholders	3,208,718
Multiplied by the fair value per share of Aerpio common stock on August 26, 2021	$	33.00
Fair value of Aerpio common stock	105,887,694
Aadi transaction costs	4,500,864
Purchase price	$	110,388,558

Summary of Allocation of Purchase Price

The allocation of the purchase price is as follows (amounts in thousands):


	August 26, 2021
Cash and cash equivalents	$	29,700
Other current assets	2,709
Intangible asset (1)	78,062
Deposits	20
Accounts payable and accrued liabilities	(103)
Purchase price	$	110,388


			(1)			The long-lived intangible asset represented Aerpio’s out-licensing agreement with Gossamer Bio., Inc. In accordance with GAAP for asset acquisitions, the excess purchase price over the fair value of the acquired assets and liabilities was ascribed to the acquired contract intangible asset. Subsequently, the Company recorded an impairment and the licensing agreement was terminated. See Note 6 for additional information.